Zymogenetics, Inc.

Osteoscreen, Inc.

Other

University of Texas System

Osteoscreen Ip, LLC

Nand Baindur

Kirk G Robbins

Gregory R Mundy

Charles R Petrie

Mark W Orme

Virender M Labroo

Paul O Sheppard

Patricia A McKernan

Theresa Martinez

Maria Kontoyianni

Robert R West

Shirley R Gasper

Paul D Bishop

Scott M Harris

James L Holloway

David A Adler

Stephanie Beigel-Orme

Theresa A Deisher

Laurence H Hurley

Sean Michael Kerwin

Emma E Moore

Stephanie Beigel

Steven Stroop

David W Taft

Mark V Craig

The present invention relates to polynucleotide and polypeptide molecules for zamp1, a novel member of the &#x3b2;-defensin family. The polypeptides, and polynucleotides encoding them, exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The present invention also includes antibodies to the zamp1 polypeptides.

Beta-defensins

The present invention relates to human polynucleotide and polypeptide molecules for zdint1, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are believed to be cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the zdint1 polypeptides.

Polynucleotides encoding disintegrin homologs, and related products

The topical administration of statins for the treatment of bone disorders is disclosed.

Topical administration of statins for treatment of bone disorders

The present invention relates to polynucleotide and polypeptide molecules, and variants thereof, for MAPP, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the MAPP polypeptides.

Mammalian adhesion protease peptides

Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or &ldquo;linker&rdquo; defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 &angst;, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.

Compositions and methods for treating bone deficit conditions

Isoprenoid pathway inhibitors for stimulating bone growth

The present invention relates to polynucleotide and polypeptide molecules for zamp1, a novel member of the &bgr;-defensin family. The polypeptides, and polynucleotides encoding them, exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The present invention also includes antibodies to the zamp1 polypeptides.

Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.

Calcitonin mimetics

Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.

The present invention relates to polynucleotide and polypeptide molecules for zdint1, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are believed to be cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the zdint 1 polypeptides.

Disintegrin homologs

Growing community of inventors

Edmonds, WA, United States of America

Nand Baindur